While this cross-trial comparison should be interpreted cautiously, the stronger anti-tumour response observed with the combination may be due to the overlapping mechanisms of BGB-A333 and tislelizumab increasing the inhibition of the PD-1/PD-L1/PD-L2 pathway and blocking more immuno-suppressive signals than tislelizumab alone. Here, PDCD1LG2 is linked to neoplasm.